Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a Healthcare company (Biotechnology) with a market capitalization of $10.9B. The Maz Rating grades it against the other companies in its sector.
Halozyme Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $95.97, Halozyme Therapeutics, Inc. trades at 22.8x trailing earnings and 6.1x sales, with an EV/EBITDA of 16.3. Over the last twelve months it generated about $1.8B of revenue and $479M of net income. It runs a gross margin of 82.3%, an operating margin of 55.9% and a net margin of 26.9%. It shows return on equity of 544.3%, return on invested capital of 22.6% and a free cash flow yield of 8.1%. On the balance sheet: a debt-to-equity ratio of -58.84 and a current ratio of 3.88. Over the past 52 weeks the share price ranged from $61.23 to $134.00, with a beta of 0.90.
Halozyme Therapeutics, Inc. does not currently pay a dividend.
27 Wall Street analyst ratings cover the stock: 16 Buy, 10 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Halozyme Therapeutics, Inc. (HALO) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 24.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.19% / 30% · Interest income / Revenue 0.44% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 24.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.19% / 33% · Receivables / Mkt Cap (36m) 4.01% / 49% · Interest income / Revenue 0.44% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 24.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.19% / 33.33% · Receivables / Mkt Cap (24m) 4.01% / 33.33% · Interest income / Revenue 0.44% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 86.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 15.7% / 33.33% · Receivables / Avg Assets (4Q) 16.7% / 33.33% · Interest income / Revenue 0.44% / 5% | Fail |
| FTSE | Debt / Total Assets 93.6% / 33.33% · (Cash+ST Inv) / Total Assets 30.9% / 33.33% · (Cash+Recv) / Total Assets 46.1% / 33.33% · Interest income / Revenue 0.44% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Halozyme Therapeutics, Inc. (HALO) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Halozyme Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.44% of each dividend: Halozyme Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.